Indaptus Therapeutics
INDPIndaptus Therapeutics, Inc. (NASDAQ: INDP) is a clinical-stage biotechnology company based in the United States. The company's primary business focus is the development of novel immunotherapies for the treatment of cancer and viral infections. Its research is centered on a proprietary approach known as the Decoy platform, which is designed to simultaneously target multiple pathways within the innate and adaptive immune systems. The company's lead product candidate, INDP-101, is a systemically administered, killed, non-pathogenic bacterial vector. It is engineered to deliver multiple pathogen-associated molecular patterns (PAMPs) to stimulate a broad immune response. Indaptus is currently evaluating INDP-101 in clinical trials for patients with advanced solid tumors. The therapeutic strategy aims to induce both direct anti-tumor activity and enhance the efficacy of other immunotherapies, such as checkpoint inhibitors. As a publicly traded entity, Indaptus Therapeutics operates within the competitive biotech and immunotherapy sectors. Its ongoing clinical work is directed toward addressing significant unmet medical needs in oncology, with a specific focus on leveraging its Decoy platform technology to modulate immune system responses against malignant cells and viral pathogens.
INDP · Stock Price
Historical price data
About
Indaptus Therapeutics, Inc. (NASDAQ: INDP) is a clinical-stage biotechnology company based in the United States. The company's primary business focus is the development of novel immunotherapies for the treatment of cancer and viral infections. Its research is centered on a proprietary approach known as the Decoy platform, which is designed to simultaneously target multiple pathways within the innate and adaptive immune systems. The company's lead product candidate, INDP-101, is a systemically administered, killed, non-pathogenic bacterial vector. It is engineered to deliver multiple pathogen-associated molecular patterns (PAMPs) to stimulate a broad immune response. Indaptus is currently evaluating INDP-101 in clinical trials for patients with advanced solid tumors. The therapeutic strategy aims to induce both direct anti-tumor activity and enhance the efficacy of other immunotherapies, such as checkpoint inhibitors. As a publicly traded entity, Indaptus Therapeutics operates within the competitive biotech and immunotherapy sectors. Its ongoing clinical work is directed toward addressing significant unmet medical needs in oncology, with a specific focus on leveraging its Decoy platform technology to modulate immune system responses against malignant cells and viral pathogens.